Retrospective Analysis Of Type Of Kras Mutation (Mut) And Response To First-Line Platinum-Based Chemotherapy (Pc) In Non-Small Cell Lung Cancer (Nsclc) Patients (Pts)

8061 Background: Improving clinical outcome of pts with advanced NSCLC with a KRAS mut is challenging. Previous research indicated that different types of KRAS mut respond differently to chemotherapy regimens. This may impact treatment strategy in this group of pts. Methods: Consecutive pts with advanced NSCLC and known KRAS mut status, treated with first-line PC were retrieved from different hospital databases. Primary objective: Differences in overall response rate (ORR), progression free survival (PFS) and overall survival (OS) between different types of PC per type of KRAS mut. Χ2-test and log rank test were used and pts were stratified by KRAS amino acid substitution (sub). Results: 305 pts (92% stage IV) from 10 hospitals, treated between 2008 and 2013, were included. Most common mut were G12C (47%), G12V (20%) and G12D (10%); 90% of pts had a codon 12 mut. Pts were treated with cisplatin (n=155) or carboplatin (n=150), combined with pemetrexed (PEM; n=194), gemcitabine (GEM; n=50), taxanes (TAX; n=...